GlassScriptPhysician profile
Edgardo Li Espino
NPI 1285768432
$3,009.89
in general payments reported to CMS, 2019-2025
18 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $540 · 2021: $507 · 2022: $239 · 2023: $326 · 2024: $360 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $549.45 | 2019-2025 | Rezzayo, Kimyrsa |
| Merck Sharp & Dohme LLC | $459.26 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $424.40 | 2019-2020 | |
| Insmed, INC. | $372.37 | 2019-2025 | Arikayce |
| Abbvie INC. | $236.55 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $232.00 | 2021-2025 | Nuzyra |
| Astellas Pharma US INC | $211.91 | 2019-2022 | |
| Gilead Sciences, INC. | $167.04 | 2019-2023 | Veklury |
| Ferring Pharmaceuticals INC. | $129.14 | 2023-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $63.68 | 2024-2025 | Vowst |
| Viiv Healthcare Company | $31.27 | 2025 | Cabenuva |
| Theratechnologies INC. | $30.13 | 2021 | |
| Nestle Healthcare Nutrition INC. | $22.85 | 2023 | |
| Shionogi INC | $18.32 | 2023 | Fetroja |
| Nabriva Therapeutics, Plc | $17.20 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17.01 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $15.00 | 2019 | |
| Tactile Systems Technology INC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgardo Li Espino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.